These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
615 related articles for article (PubMed ID: 11769299)
1. A practice-based approach for converting from proton pump inhibitors to less costly therapy. Lucas LM; Gerrity MS; Anderson T Eff Clin Pract; 2001; 4(6):263-70. PubMed ID: 11769299 [TBL] [Abstract][Full Text] [Related]
2. Proton pump inhibitors or histamine-2 receptor antagonists for the prevention of recurrences of erosive reflux esophagitis: a cost-effectiveness analysis. Harris RA; Kuppermann M; Richter JE Am J Gastroenterol; 1997 Dec; 92(12):2179-87. PubMed ID: 9399748 [TBL] [Abstract][Full Text] [Related]
3. Therapy with gastric acidity inhibitors increases the risk of acute gastroenteritis and community-acquired pneumonia in children. Canani RB; Cirillo P; Roggero P; Romano C; Malamisura B; Terrin G; Passariello A; Manguso F; Morelli L; Guarino A; Pediatrics; 2006 May; 117(5):e817-20. PubMed ID: 16651285 [TBL] [Abstract][Full Text] [Related]
4. Lansoprazole overutilization: methods for step-down therapy. Pohland CJ; Scavnicky SA; Lasky SS; Good CB Am J Manag Care; 2003 May; 9(5):353-8. PubMed ID: 12744297 [TBL] [Abstract][Full Text] [Related]
5. A cost-effectiveness analysis of prescribing strategies in the management of gastroesophageal reflux disease. Gerson LB; Robbins AS; Garber A; Hornberger J; Triadafilopoulos G Am J Gastroenterol; 2000 Feb; 95(2):395-407. PubMed ID: 10685741 [TBL] [Abstract][Full Text] [Related]
6. Assessment of patient satisfaction with a formulary switch from omeprazole to lansoprazole in gastroesophageal reflux disease maintenance therapy. Condra LJ; Morreale AP; Stolley SN; Marcus D Am J Manag Care; 1999 May; 5(5):631-8. PubMed ID: 10537869 [TBL] [Abstract][Full Text] [Related]
7. Large variations in prescriptions of gastrointestinal medications in hemodialysis patients on three continents: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Bailie GR; Mason NA; Elder SJ; Andreucci VE; Greenwood RN; Akiba T; Saito A; Bragg-Gresham JL; Gillespie BW; Young EW Hemodial Int; 2006 Apr; 10(2):180-8. PubMed ID: 16623672 [TBL] [Abstract][Full Text] [Related]
8. Proton pump inhibitors. Compliance with a mandated step-up program. Mamdani MM; Tu K; Jaakkimainen L; Bica A; Hux J Can Fam Physician; 2001 Mar; 47():531-5. PubMed ID: 11281086 [TBL] [Abstract][Full Text] [Related]
9. Step-down from multiple- to single-dose proton pump inhibitors (PPIs): a prospective study of patients with heartburn or acid regurgitation completely relieved with PPIs. Inadomi JM; McIntyre L; Bernard L; Fendrick AM Am J Gastroenterol; 2003 Sep; 98(9):1940-4. PubMed ID: 14499769 [TBL] [Abstract][Full Text] [Related]
11. Impact of proton pump inhibitor utilization patterns on gastroesophageal reflux disease-related costs. Hall J; Dodd S; Durkin M; Sloan S Manag Care; 2002 Jul; 11(7 Suppl):14-8. PubMed ID: 12181872 [TBL] [Abstract][Full Text] [Related]
12. The extent and determinants of prescribing and adherence with acid-reducing medications: a national claims database study. El-Serag HB; Fitzgerald S; Richardson P Am J Gastroenterol; 2009 Sep; 104(9):2161-7. PubMed ID: 19568229 [TBL] [Abstract][Full Text] [Related]
13. Rational prescribing: practice audit and drug switch in dyspepsia management. Dott AG; Johnson L Int J Clin Pract; 1999 Dec; 53(8):599-603. PubMed ID: 10692753 [TBL] [Abstract][Full Text] [Related]
14. [Cost-effectiveness of the treatment of reflux esophagitis: proton pump inhibitor versus histamine-2-receptor antagonist]. Habu Y; Oyasu K; Wakamatsu T; Sumitomo Y; Kiyota K; Inokuchi H; Kawai K Nihon Rinsho; 2000 Sep; 58(9):1881-5. PubMed ID: 11004820 [TBL] [Abstract][Full Text] [Related]
15. A therapeutic substitution policy for proton pump inhibitors: clinical and economic consequences. Schneeweiss S; Maclure M; Dormuth CR; Glynn RJ; Canning C; Avorn J Clin Pharmacol Ther; 2006 Apr; 79(4):379-88. PubMed ID: 16580906 [TBL] [Abstract][Full Text] [Related]
16. Evaluation of use of proton pump inhibitors in Greece. Ntaios G; Chatzinikolaou A; Kaiafa G; Savopoulos C; Hatzitolios A; Karamitsos D Eur J Intern Med; 2009 Mar; 20(2):171-3. PubMed ID: 19327607 [TBL] [Abstract][Full Text] [Related]
17. A simple institutional educational intervention to decrease use of selected expensive medications. Roth EJ; Plastaras CT; Mullin MS; Fillmore J; Moses ML Arch Phys Med Rehabil; 2001 May; 82(5):633-6. PubMed ID: 11346840 [TBL] [Abstract][Full Text] [Related]
18. Cost analysis of a provincial drug program to guide the treatment of upper gastrointestinal disorders. Bursey F; Crowley M; Janes C; Turner CJ CMAJ; 2000 Mar; 162(6):817-23. PubMed ID: 10750472 [TBL] [Abstract][Full Text] [Related]
19. Proton pump inhibitors: perspectives of patients and their GPs. Grime J; Pollock K; Blenkinsopp A Br J Gen Pract; 2001 Sep; 51(470):703-11. PubMed ID: 11593830 [TBL] [Abstract][Full Text] [Related]
20. Reducing outpatient costs of nonsteroidal antiinflammatory drugs at a Department of Veterans Affairs teaching hospital. Drexler PG; Lambdin CS J Pharm Technol; 1993; 9(1):10-3. PubMed ID: 10123760 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]